The editor of eLife, on the eve of accepting his Nobel Prize, publishes an article designed to give his journal a competitive advantage. Unfortunately, the errors, lack of disclosure of his incentives, and inappropriate dismissal of incentives made the social graph light up with derision.
eLife is beginning to accept papers, but is it proper for them to promote papers they’ve accepted without having published the final versions? What will their approach be to media embargoes?
Can a new open access journal that relies on working scientists to oversee its review process compete with other top-tier journals that employ professional editors?